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Abstract 
Background 
Patients frequently require several lines of therapy for treatment of major depressive episodes. This 
economic analysis details the management of patients who responded inadequately due to lack of 
efficacy or intolerability to two previous antidepressants in the UK.    
Methods 
The model included a decision tree and a Markov component. Health states considered in the 
decision tree were remission, response, no response, withdrawal due to adverse events, relapse, 
recovery, and recurrence. The time horizon was 24 months. Patients were on third-line treatment for 
up to a 3-month acute phase and a 6-month maintenance phase. As third-line efficacy data were not 
available, inputs were calculated by adjusting original second-line data to third-line based on 
proportionate reductions observed in STAR*D. Equivalent efficacy was assumed for all comparators. 
Healthcare resource use and utilities were based on UK estimates.  
Results 
Vortioxetine was a cost-effective treatment option at a threshold of £20,000/QALY vs. escitalopram, 
citalopram, sertraline, and was associated with more health benefits, less costs (was dominant) 
versus relevant third-line comparators venlafaxine and duloxetine. Agomelatine was found not to be a 
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cost-effective option. The 22-month maintenance phase treatment scenario results were similar to the 
6-month base case.  
Limitations 
Third-line efficacy data were not available. This highlights the need for studies in patients receiving 
third-line treatment.  
Conclusion 
This model provides an overview for the management of patients receiving third-line treatment where 
limited evidence currently exists. Vortioxetine, with its novel mechanism of action, is expected to be a 
dominant treatment option versus relevant comparators in the UK.  
Keywords 
Major depressive disorder, depression, cost-utility analysis, inadequate response, vortioxetine.  
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Introduction/Background  1 
Major Depressive Disorder (MDD) is a common and frequently recurrent mood disorder. MDD as a 2 
recurrent disorder comprises at two or more major depressive episodes (MDEs). 3 
 4 
This psychiatric disorder is characterized by symptoms interfering with the daily life of patients, such 5 
as lack of enjoyment in activities, feelings of sadness, guilt, anxiety, and recurrent thoughts of death 6 
and suicide (1). It may also harm the wellbeing of family members, including children. Being the child 7 
of a depressed parent carries a greatly increased risk of suffering from depression for the child 8 
involved. As many as 40 percent of the children of depressed parents will suffer from depression 9 
before 20 years of age (1, 2). The number of adult patients experiencing a moderate-to-severe MDE 10 
and receiving switch antidepressant therapy is estimated at approximately 700,000 to 1.2 million per 11 
annum based on mid-2013 figures from the Office for National Statistics (ONS) in the United Kingdom 12 
(UK) (3) (4). Patients who have encountered multiple episodes or multiple lines of treatment are at a 13 
greater risk of suicide attempts (5), hospital admissions (6), and impaired work productivity (7). 14 
Therefore, the need to achieve early control in MDD highlights the importance of having effective and 15 
well-tolerated treatment options available in the event of inadequate response to a first treatment. In 16 
case of absent or minimal response after 8 weeks of treatment, the National Institute for Health and 17 
Care Excellence (NICE) CG90  guidelines recommend switching to another antidepressant, newer-18 
generation or different class (8, 9). The NICE guidelines as published by NICE, which is the main 19 
health technology assessment body in the UK, provide evidence-based guidance, advice and 20 
information services for health, public health and social care professionals. The NICE CG90 21 
guidelines cover identification and management of depression in adults, in both the primary and 22 
secondary care settings in the UK.   23 
MDD is associated with heterogeneity in terms of both patients and treatments. Therefore, a strict 24 
treatment strategy is unlikely to be optimal, particularly at latter lines of therapy. Due to the recurrent 25 
nature of depression, in addition to the high treatment failure rate attributable to inadequate efficacy or 26 
intolerability, clinicians aim to match the treatment to the individual, taking into account their treatment 27 
and family history, where applicable. This is an approach that is supported by both NICE CG90 28 
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guidelines (9) on the treatment and management of depression, and expert opinion. Despite the 29 
range of currently available therapies, there is an unmet need for tailored treatments, according to 30 
individual patient’s profile and history. Such treatments should have a different mode of action and 31 
offer equivalent efficacy to other, widely used antidepressants alongside a favourable tolerability 32 
profile.  33 
Vortioxetine is an efficacious and well-tolerated, once-daily, orally-administered treatment option for 34 
MDD (10). It is an antidepressant with a novel mechanism of action that is thought to work through a 35 
combination of serotonin reuptake inhibition and modulation of serotonin receptor activity (10). In 36 
addition, pre-clinical and clinical data provide evidence to demonstrate the effect of vortioxetine on 37 
cognitive symptoms of MDD (11, 12). Vortioxetine offers significant and clinically relevant 38 
improvement in efficacy versus agomelatine (REVIVE; Montgomery et al. 2014) and was generally 39 
well tolerated in terms of sexual dysfunction versus escitalopram (TAK 318; Jacobsen et al. 40 
2015).(13) An indirect-treatment-comparison (ITC) was also conducted in switch patients showing that 41 
vortioxetine leads to numerically higher remission rates compared with sertraline, venlafaxine, 42 
bupropion and citalopram. Vortioxetine is a well-tolerated treatment, with a statistically lower 43 
withdrawal rates due to AEs compared with these antidepressants. (14) (15) 44 
Vortioxetine has been recently approved by NICE as an option for treating MDE in adults whose 45 
condition has responded inadequately to two antidepressants within the current episode. Detail on the 46 
process can be found in the NICE technology appraisal guidance for vortioxetine (TA367) and the 47 
Evidence Review Group critique in Lomas 2016. (14, 16)  48 
This paper details the economic model and analysis that was considered in the NICE evaluation of 49 
vortioxetine for patients receiving third-line treatment in the UK. 50 
Methods 51 
The population consists of patients who have responded inadequately to two antidepressants within 52 
the current episode; referring to third-line in the treatment pathway for their MDE. This includes 53 
patients who have experienced a lack of efficacy or/and intolerability to their previous two treatments. 54 
The model required making a number of assumptions, which are explicitly described in this section 55 
and in the ‘limitations’ section at the end of this manuscript. 56 
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 57 
 58 
Model structure 59 
In order to ensure the model structure was reflective of UK clinical practice, a comprehensive review 60 
of both national and local guidelines, along with current clinical practice through both questionnaires 61 
and an advisory board have been undertaken. The structure has been adapted from a model 62 
presented in Trivedi et al. 2004 (17), a review on existing models in the NICE depression guidelines 63 
(9) and a model developed by The Dental and Pharmaceutical Benefits Agency (TLV ) in Sweden (1). 64 
Patients were diagnosed using the Diagnostic and Statistical Manual of Mental Disorders (DSM IV) 65 
criteria. The DSM diagnostic criteria for MDD are well recognised and widely used in trial settings, 66 
with DSM IV being employed in the trials of vortioxetine (18). 67 
The model (available on request) consisted of both a decision tree and a Markov component (Figure 68 
1), with patients entering the model at the third-line of treatment. In the acute phase, patients could 69 
follow one of the following 4 clinical pathways: remission, response but no remission, no response, or 70 
withdrawal due to AEs. Response was defined as a 50% or more reduction in symptoms from 71 
baseline values on Montgomery–Asberg Depression Rating Scale (MADRS) or Hamilton Depression 72 
Rating Scale (HAM-D), and remission as MADRS≤10 or HAM-D7. Patients who experienced 73 
response but no remission at 8 weeks were assumed to be reassessed at week 12. This was 74 
informed by clinical opinion which suggested that an additional 4 weeks on treatment would allow for 75 
the treatment effect to be fully achieved. If a patient had achieved remission (8 or 12 weeks) or was in 76 
response at week 12 they entered the maintenance phase of the model. Patients in no response (8 or 77 
12 weeks) switched to another line of therapy and entered the Markov component. This is consistent 78 
with the British Association for Psychopharmacology (BAP) 2015 guidelines which recommend that if 79 
a patient has had complete lack of response at 4 weeks and previously failed multiple treatments, 80 
they should continue on treatment for another 2-6 weeks. Moreover, clinical experts have suggested 81 
that switch at 8 weeks due to no response was reflective of practice (19). Furthermore, a previous 82 
cost-utility analyses based on the STAR*D trial shows that switching antidepressants after insufficient 83 
response increased remission rates (20). A change of treatment at 4 weeks was assumed for patients 84 
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withdrawing due to adverse events, based on internally sourced data, where the majority of patients 85 
who stopped treatment due to adverse events withdrew by 4 weeks (21). During the acute phase 86 
patients incurred the risk of treatment specific short-term AEs (sexual AEs, dry mouth, nausea, 87 
sweating, headache, somnolence, diarrhoea, insomnia and dizziness) which were independent of 88 
each other.   89 
The maintenance phase of treatment was considered to be 6 months. This was in line with the 90 
minimum recommended treatment period for an antidepressant once symptoms have been resolved 91 
and is informed by antidepressant regulatory licenses and NICE guidelines. Once a patient entered 92 
the maintenance phase they were subject to a risk of relapse and treatment specific long-term AEs 93 
(sexual dysfunction, weight gain and insomnia) which led to treatment switch. A patient who 94 
maintained remission for 6 months entered recovery. In this health state the risk of recurrence was 95 
considered. Patients who switched to fourth and subsequent lines of treatment or achieved recovery 96 
entered the recursive Markov part of the model.  97 
The overall time horizon was 24 months. This allowed for representation of patients with a history of 98 
recurrent episodes.   99 
Comparators 100 
In the UK, the initial recommended treatment is a generic selective serotonin reuptake inhibitor 101 
(SSRI). If a patient is required to switch treatment due to lack of efficacy or intolerability, an alternative 102 
SSRI or newer generation, better tolerated antidepressant is suggested. At third-line of treatment 103 
CG90 guidelines recommend patients switch to an antidepressant of a different class (i.e. serotonin-104 
norepinephrine reuptake inhibitors [SNRIs]), with tolerability issues including discontinuation 105 
symptoms a key decision maker in treatment (9). The comparators considered in this analysis were 106 
the SNRIs (duloxetine and venlafaxine). Additionally, agomelatine was included due to the availability 107 
of head-to-head data with vortioxetine. The results compared to the SSRIs (escitalopram, citalopram 108 
and sertraline) were also provided.   109 
Data sources and clinical evidence  110 
As no third-line data for vortioxetine were available, base case and scenario analyses were performed 111 
using several data sources in both the broad MDD population and patients who switched after 112 
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inadequate response (second-line). A detailed assessment of the data sets is provided in the 113 
supplementary material.  114 
 115 
Discussion on the data sets 116 
The systematic literature review associated with the Switch network (NICE TA367 submission [2015] 117 
and Brignone et al. [2014]) established that a limited number of RCT existed in a switch population 118 
(i.e. patients starting their second-line of treatment). (14) (22) Montgomery et al. (2014) (10) is a 119 
head-to-head trial of vortioxetine and agomelatine in switch patients [REVIVE] which established that 120 
vortioxetine had superior efficacy compared to agomelatine. Due to its design, REVIVE provides 121 
robust evidence for consideration in this cost-utility model. REVIVE was used as a starting point for 122 
the Switch network. This indirect treatment comparison provides comparative evidence focusing on 123 
the switch population. The results indicated that vortioxetine was more efficacious as measured by 124 
change from baseline symptom scores and response, in addition to better tolerability based on 125 
withdrawals due to AEs (statistically significant differences vs. sertraline, venlafaxine and bupropion). 126 
However, the heterogeneity within the included studies may limit the robustness of conclusions.   127 
Llorca et al. (2014) (23) provided robust comparative evidence on the symptom score reductions (as 128 
measured by the change from baseline to 8 weeks on severity scales e.g. MADRS or HAM-D) and 129 
withdrawals due to AEs in the broad MDD population. The overall conclusion was the following, 130 
comparable efficacy between antidepressants and an advantage in tolerability for vortioxetine versus 131 
commonly used antidepressants. Secondary analyses on response and remission were also 132 
undertaken. However, these outcomes were not considered to be sufficiently robust as remission and 133 
response were not the primary efficacy endpoints in many of the studies that were included, and it 134 
was observed that these outcomes were not systematically reported in the publications 135 
The analysis conducted in Pae et al. (2014) (24) included vortioxetine data from active reference and 136 
active comparator studies in broad MDD. In some of the placebo-controlled studies, an active 137 
reference was included as internal control. As acknowledged by the European Medicines Agency in 138 
the European Public Assessment Report, the exclusion of non-responders and the inclusion of 139 
previous responders in the active reference arm could have introduced a bias in favour of the efficacy 140 
  Page 8 
of the active reference. Therefore, differences in the efficacy of vortioxetine versus the active 141 
reference cannot be inferred on the basis of these studies. These results should be interpreted with 142 
caution. (25) 143 
Wang et al. (2015) (26), a RCT comparing vortioxetine to venlafaxine in an Asian population 144 
[SOLUTION] was conducted in broad MDD. UK clinical experts stated that the relative effect is 145 
unlikely to differ between European and Asian populations. Non-inferiority in efficacy was concluded 146 
for vortioxetine compared to venlafaxine, however vortioxetine was associated with significantly fewer 147 
withdrawals due to AEs. 148 
After comparison of the data sets, including strengths, weaknesses and results, the base case 149 
analyses assumed equivalent efficacy between treatments (based on estimates for vortioxetine from 150 
REVIVE) but incorporated the individual tolerability profiles of each antidepressant. This approach 151 
was aligned with the NICE appraisal conclusions, which stated that based on the total evidence, 152 
vortioxetine is likely to be of similar efficacy to other antidepressants in addition to a better overall 153 
tolerability profile. (14) Equivalent efficacy is further supported by NICE depression guidelines which 154 
concluded that generally antidepressants have largely equal efficacy. (9) 155 
Model parameters 156 
Efficacy and Tolerability parameters 157 
The remission rate was taken from Montgomery et al. (2014) which provides evidence at second-line 158 
of treatment.(10) In order to adjust estimates to third-line, a proportionate reduction from second to 159 
third-line observed in STAR*D was applied to the vortioxetine absolute values for remission and no 160 
response (see supplementary material). As equivalent efficacy was considered, the values of 18.1% 161 
and 44.8% for remission and no response respectively were applied for all comparators in the model. 162 
The response rate of 37.1% was calculated as one minus the probability of remission and of no 163 
response (Table 1). The rates of withdrawal due AEs were subtracted directly from the proportion of 164 
patients in no response. This was validated by clinical opinion and an analysis of Montgomery et al. 165 
(2014) data which demonstrated that patients withdrawing due to AEs remained in the no response 166 
health state.  167 
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The efficacy values at 12 weeks were calculated based on conditional probabilities observed in the 168 
REVIVE study. Patients in the response health state at 8 weeks had a 59.92%, 32.14% and 8.33% 169 
probability of being in remission, response and no response at 12 weeks respectively (Table 1). 170 
These values were assumed to be applied to all comparators in the model due to lack of individual 171 
patient data for some comparators; and were consistent with the approach proposed by NICE. 172 
Similarly, relapse and remission at subsequent lines of treatment were also not considered to be 173 
treatment-specific, as observed in studies discussed by Limosin et al. (2004) and STAR*D 174 
respectively (4, 27).  175 
Patients who achieve recovery face a two-month probability of recurrence (0.44%; See 176 
supplementary material for equations). This value was derived from a publication by Hardeveld et al. 177 
(2013). (28) The estimate was taken from a 10-year recurrence probability that was adjusted to reflect 178 
the two month cycles of the model.  179 
Furthermore, spontaneous recovery was considered for the model. However, it was not included as it 180 
would require further assumptions, which would add complexity to the model and, at the same time, it 181 
would not change the overall conclusion of the study. 182 
Table 1. Efficacy inputs   183 
 Remission No response Response Relapse Recurrence 
0 – 8 weeks      
 3rd   line 18.1%* 44.8%*^ 37.1%¥ 14.2%(27) NA 
8 - 12 weeks 
 3rd   line 59.52% 32.14% 8.33%¥ 14.2%(27) NA 
Switch lines      
4th line 13.0%(4) NA NA 25.0% 0.44%(28) 
5th line 13.0%(4) NA NA 42.6%(4) 0.44%(28) 
6th  line 13.0%(4) NA NA 42.6%(4) 0.44%(28) 
*Proportional reduction in efficacy from 2nd to 3rd line applied from STAR*D applied to REVIVE vortioxetine rates 184 
^rates of withdrawals due to AEs subtracted from this. 185 
 ¥ Response = 1 – remission – no response 186 
Tolerability data for short-term events (Table 2) were retrieved from Montgomery et al. (2014) (10) for 187 
vortioxetine and agomelatine, and Cochrane reviews for the comparators sertraline (Cipriani et al. 188 
2010) (29), citalopram (Cipriani et al. 2012) (30), escitalopram (Cipriani et al. 2009)(31) and 189 
duloxetine (Cipriani et al. 2012) (30). Long-term AEs (Table 2) occurring during the maintenance 190 
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phase were informed by Goodwin et al.  (2009) (32) for agomelatine and Bet et al. (2013) (33) for 191 
sertraline, venlafaxine, citalopram, escitalopram and duloxetine. Pooled long-term extension studies 192 
provided the evidence for vortioxetine long-term AEs (34). Adverse-events were considered to be 193 
independent of each other. Therefore, patients could experience one or several AEs.  194 
Table 2. Adverse event probabilities  195 
  Vortioxetine 
 
Agomelatine 
 
Sertraline 
 
Venlafaxine Citalopram 
 
Escitalopram 
 
Duloxetine 
 
Withdrawal 
due to AES¥  
5.93% 9.50% 26.90% 28.20% 28.20% 28.20% 28.20% 
Short-term         
Sexual 
dysfunction 
0.40% 0.00% 10.64% 14.38% 6.24% 6.69% 3.77% 
Dry mouth 4.74% 3.31% 14.45% 23.02% 6.68% 7.93% 15.00% 
Nausea 16.21% 9.09% 26.17% 41.02% 10.99% 15.28% 30.27% 
Sweating 2.37% 2.07% 13.34% 12.87% 6.50% 5.21% 8.85% 
Somnolence 4.00% 7.85% 9.15% 8.58% 6.85% 6.56% 9.15% 
Headache 10.28% 13.22% 26.08% 21.62% 10.85% 15.71% 15.59% 
Diarrhoea 3.16% 3.31% 20.14% 8.95% 6.74% 8.33% 7.65% 
Insomnia 7.10% 2.89% 18.10% 17.96% 7.46% 8.88% 12.30% 
Dizziness 7.11% 11.57% 10.40% 13.24% 4.58% 5.34% 11.36% 
Long term         
Sexual 
dysfunction 
1.56% 0.00% 23.00% 31.00% 23.00% 23.00% 31.00% 
Insomnia 3.50% 1.80% 7.00% 10.00% 7.00% 7.00% 10.00% 
Weight gain 2.90% 0.00% 19.00% 17.00% 19.00% 19.00% 17.00% 
 
¥
Withdrawal due to AEs were subtracted from no response 196 
Venlafaxine pooled Cochrane reviews  197 
Utilities 198 
Utility values (Table 3) for all efficacy health states were informed by applying the UK preference 199 
algorithm to the REVIVE EQ-5D data. (35) Disutilities were applied to the AEs and taken from Sullivan 200 
et al. (2004) (36) for all events except weight gain - this value was calculated based on information in 201 
Dixon et al. (2004). (37) 202 
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Table 3. Utilities according to health states and disutilities associated with adverse events  203 
Utilities  Value 
Acute phase 0-8 weeks Depression at baseline 0.54 
Remission 0.85 
Response without remission 0.76 
No response 0.56 
Acute phase 8-12 weeks Remission 0.85 
Response without remission 0.76 
No response 0.56 
Maintenance phase Remission 0.85 
Response without remission 0.76 
Relapse 0.56 
Recovery 0.85 
Recurrence 0.56 
Disutilities    
Short-term and long-term adverse events Sexual dysfunction 0.049 
Headache 0.115 
Diarrhoea 0.044 
Somnolence 0.085 
Nausea 0.065 
Insomnia 0.129 
Dry mouth 0 
Dizziness 0 
Sweating 0 
Weight gain 0.032 
Source utilities; REVIVE (10); disutilities: Sullivan 2004 (36) 204 
The utility and disutility values are applied to the health states. These weights allow the Quality 205 
Adjusted Life Year (QALY) to be calculated. This is the main outcome of interest in this model and the 206 
measure of effectiveness.  207 
Resource Use and Costs 208 
An observational study (PERFORM) provided evidence for the resource use by health states in the 209 
acute phase in the UK.(38) However, it was not possible to differentiate between the UK resource use 210 
associated with remission and response as the response definition in PERFORM includes patients in 211 
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remission. This was also the case for the maintenance phase with data provided from Byford et al. 212 
(2011), the only identifiable UK source. (39) Therefore an assumption of equal resource use for 213 
response and remission was applied. This was considered to be a conservative approach, validated 214 
by expert opinion, as resource use may be underestimated for response. See supplementary material 215 
for detailed resource use data (Table 8). Unit costs (Table 4) were informed by the 2013 Personal 216 
Social Services Unit (PSSRU) and the National schedule of reference costs (40) (41). Finally, a 217 
discount rate of 3.5% was applied to both costs and outcomes in the second year. 218 
Table 4. Resource use unit cost 219 
Resource  Unit cost (£) 
GP consultations 45 
Psychiatrist consultations   125 
Psychotherapy or counselling   145 
Psychiatric ward admissions   342 
General ward admissions   697 
Accident & emergency visits   177 
Source: 2013 Personal Social Services Unit (PSSRU) and the National schedule of reference costs (40) (41) 220 
Analyses  221 
The results of the model were presented based on the Incremental Cost Effectiveness Ratio (ICER). It 222 
is the difference in cost divided by the difference in effect (QALY) between two treatments. In the UK, 223 
an acceptable cost-effectiveness threshold considered by NICE is £20,000 – £30,000/QALY. This is 224 
the cost the UK NHS are willing to pay for an additional QALY gained. Scenario analyses were 225 
conducted to reflect the uncertainty in model structure, duration of maintenance phase and the setting 226 
of care. The maintenance phase was further investigated in a scenario of 22 months. This was based 227 
on UK guidelines (NICE CG90 and BAP) which have stated high risk patients (e.g. more than 5 228 
lifetime episodes and/or 2 episodes in the last few years) should receive treatment for up to 2 years. 229 
(9) (19) Additionally, an analysis considering management in secondary care was considered by 230 
assuming that all patients were initially treated by a psychiatrist and not a GP. A probabilistic 231 
sensitivity analysis (PSA) was performed to test the robustness of the results.  232 
 233 
 234 
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Results 235 
The ICERS based on pairwise analyses versus vortioxetine, and incremental ICERs are presented in  236 
Table 5. The base case analysis of equivalent efficacy demonstrated that vortioxetine was a cost-237 
effective treatment option versus citalopram (ICER=£4,590), escitalopram (ICER=£3,956) and 238 
sertraline (ICER=£2,746). In the comparison with venlafaxine and duloxetine, vortioxetine was a 239 
dominant strategy as it was associated with increased QALYs at a lower cost. Agomelatine had an 240 
ICER of £243,079 versus vortioxetine, which is substantially above the NICE threshold and therefore 241 
cannot be considered a cost-effective option according to these criteria. Additionally, results based on 242 
robust head-head evidence in a switch population demonstrated that vortioxetine was a dominant 243 
strategy versus agomelatine.  244 
According to UK guidelines, a treatment with a different mechanism of action should be considered at 245 
third-line. Therefore, the results excluding SSRIs provided further evidence for the cost-effectiveness 246 
of vortioxetine as a third-line of treatment due to its dominance over venlafaxine and duloxetine.  247 
Treatments Total 
cost 
Total 
QALYs 
∆ 
Cost 
∆ QALY ICER 
(vortioxetine 
vs. 
comparator) 
∆ ICERS 
(Including 
SSRIs; 
QALY) 
∆ ICERS 
(Excluding 
SSRIs; 
QALY) 
Probability 
of 
vortioxetine 
CE at λ = 
£20,000 
Probability 
of 
vortioxetine 
CE at λ = 
£30,000 
Base case: Equivalent efficacy 
Citalopram £1,342 1.414 Ref Ref £4,590 Reference n/a 63% 65% 
Escitalopram £1,347 1.414 £5 -0.001 £3,956 Dominated n/a 62% 65% 
Sertraline £1,357 1.412 £10 -0.002 £2,746 Dominated n/a 65% 67% 
Vortioxetine £1,399 1.427 £42 0.015 Reference £4,590 Reference Reference Reference 
Venlafaxine £1,400 1.410 £1 -0.017 Dominant Dominated Dominated 65% 67% 
Duloxetine £1,549 1.411 £149 0.002 Dominant Dominated Dominated 72% 72% 
Agomelatine £1,567 1.428 £19 0.016 £243,079* £243,079* £243,079* 52% 52% 
Montgomery et al. (2014) 
Vortioxetine £1,399 1.427   Reference n/a Reference Reference Reference 
Agomelatine £1,690 1.380 £291 -0.047 Dominant n/a Dominated 98% 98% 
Treatments Total 
cost 
Total 
QALYs 
∆ 
Cost 
∆ QALY ICER 
(vortioxetine 
vs. 
comparator) 
∆ ICERS 
(Including 
SSRIs; 
QALY) 
∆ ICERS 
(Excluding 
SSRIs; 
QALY) 
Probability 
of 
vortioxetine 
CE at λ = 
£20,000 
Probability 
of 
vortioxetine 
CE at λ = 
£30,000 
Base case: Equivalent efficacy 
Citalopram £1,342 1.414 Ref Ref £4,590 Reference n/a 63% 65% 
Escitalopram £1,347 1.414 £5 -0.001 £3,956 Dominated n/a 62% 65% 
Sertraline £1,357 1.412 £10 -0.002 £2,746 Dominated n/a 65% 67% 
Vortioxetine £1,399 1.427 £42 0.015 Reference £4,590 Reference Reference Reference 
Venlafaxine £1,400 1.410 £1 -0.017 Dominant Dominated Dominated 65% 67% 
Duloxetine £1,549 1.411 £149 0.002 Dominant Dominated Dominated 72% 72% 
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Table 5. Base case results  248 
* ICERs are based on lower cost and fewer QALYs for vortioxetine, so the ICERs should be interpreted as willingness to accept 249
QALYs lost, not willingness to pay for QALYs gained. 250 
ICER: Incremental cost effectiveness ratio; QALY: quality adjusted life years; SSRI: selective serotonin reuptake inhibitor; CE: cost 251 
effectiveness; λ = threshold; ∆ = incremental 252 
Further details on the results of the scenario analyses can be found in the supplementary material. In 253 
a scenario considering the management of patients in secondary care, the cost doubled for all 254 
treatments, with QALYs remaining the same. This was due to an increase in psychiatrist visits 255 
compared to GP visits and therefore the associated healthcare cost. In this scenario, vortioxetine 256 
became the least costly treatment option compared to a ranking of fourth in the base case analyses. 257 
This resulted in a dominant ICER against all comparators except for agomelatine. However, the ICER 258 
for agomelatine compared to vortioxetine showed it not to be a cost-effective treatment option at 259 
£332,296.  260 
An extension of the maintenance phase of treatment to 22 months resulted in total costs increasing 261 
for all treatments due to greater drug acquisition costs and an increased risk of long-term AEs, as 262 
patients received treatment for longer in this scenario. The total QALYs gained generally decreased 263 
as long-term adverse events were increasing as well as the cumulative risk of relapse. In this 264 
scenario, vortioxetine was proportionally more expensive than venlafaxine compared to the base case 265 
but the ICER was considerably below the NICE threshold at £8,846/QALY. The scenario where care 266 
is conducted within a secondary care setting during the 22-month maintenance phase did not change 267 
the ranking of the cost-utility results compared to management in primary care.   268 
The probabilistic sensitivity analysis (PSA) which explores the robustness in the results demonstrated 269 
that vortioxetine was likely to be cost-effective versus all comparators at a NICE cost/QALY threshold 270 
ranging from £20,000 to £30,000. It had the highest likelihood of cost-effectiveness versus duloxetine 271 
(72%; Table 3), followed by a probability of around 60-70% versus citalopram, escitalopram, 272 
sertraline, and venlafaxine, and just over 50% compared to agomelatine.  Using data from 273 
Montgomery 2014, vortioxetine had a 98% probability of being cost-effective versus agomelatine. See 274 
supplementary material for cost-effectiveness planes.  275 
Discussion 276 
Agomelatine £1,567 1.428 £19 0.016 £243,079* £243,079* £243,079* 52% 52% 
Montgomery et al. (2014) 
Vortioxetine £1,399 1.427   Reference n/a Reference Reference Reference 
Agomelatine £1,690 1.380 £291 -0.047 Dominant n/a Dominated 98% 98% 
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Economic evaluations play an important role in identifying cost-effective treatments in depression due 277 
to its chronic nature and significant resource burden (42) (43). 278 
Vortioxetine has been recently approved by NICE as an option for treating MDE in adults whose 279 
condition has responded inadequately to two antidepressants within the current episode.  The base 280 
case pair-wise analyses showed vortioxetine to be a cost-effective treatment versus citalopram, 281 
escitalopram and sertraline when a NICE threshold of £20,000 - £30,000/QALY was considered. 282 
Vortioxetine was a dominant strategy versus venlafaxine and duloxetine. For the comparison to 283 
agomelatine, the base case analysis led to an ICER of £243,079 versus vortioxetine. The results 284 
based on Montgomery et al. (2014), demonstrated that vortioxetine had a 98% probability of being 285 
cost-effective versus agomelatine at a threshold of £20,000/QALY. These results are considered 286 
particularly robust as they are based on data from a head-to-head study.   287 
This economic model has been adapted from a previously published model conducted in switch 288 
patients in Finland and an overall MDD population in South Korea.(44) (45) In the Finnish analyses 289 
Vortioxetine was found to be a dominant treatment option versus agomelatine, sertraline and 290 
venlafaxine. Similarly, this was the case in the South Korean model with dominance observed versus 291 
venlafaxine at first-line and agomelatine at second-line. The model discussed herein was consistent 292 
with these results in terms of comparisons with venlafaxine and agomelatine (when REVIVE data 293 
were considered). Vortioxetine was not a dominant treatment option versus sertraline, but it was still 294 
considered to be cost-effective.  295 
An economic evaluation has been undertaken in Scotland comparing venlafaxine and duloxetine, the 296 
two treatments of interest to the decision problem, (Benedict et al. 2010).(46) The model evaluates a 297 
population who failed on first
-
line SSRI. The analysis considers similar health states and 298 
corresponding utilities (response: 0.68, remission: 0.79, no response: 0.55). In Benedict et al. (2010), 299 
duloxetine is associated with lower costs and greater QALYs compared to venlafaxine. The improved 300 
health gains for duloxetine are observed in the model discussed herein, but the costs are higher. 301 
Caution should be taken when comparing the results of the model. This is due to the different 302 
population of interest, longer time horizon, and the non-inclusion of tolerability and AEs in Benedict’s 303 
model. However, the range of cost-effectiveness is similar to results presented, with ICERs below 304 
£7,000/QALY.  305 
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The main updates in the structure of the model were the inclusion of response, considering 306 
recurrence after recovery, the extension of the acute phase to 3 months, and the change in the time 307 
horizon from 12 to 24 months. The updated structure was informed by a model presented in Trivedi et 308 
al. (2004) (17), in addition to a comprehensive review of UK guidelines and validation by clinical 309 
experts. This ensured applicability to the UK setting and the decision question of positioning in third-310 
line. However, these changes have required some assumptions, particularly related to the data inputs.  311 
It is also of great interest to consider the scenarios comparing primary and secondary care 312 
management, and the length of the maintenance phase (6 and 22 months) in the UK. Vortioxetine 313 
appears the cheapest treatment when considering the management of patients within secondary care. 314 
This can be explained by a better tolerability profile for vortioxetine leading to fewer patients switching 315 
and thus avoiding the higher costs associated with management. According to UK clinical guidelines, 316 
patients with a higher risk of relapse should continue on treatment for at least two years. The results 317 
of the extended 22-month maintenance phase scenario provide evidence for vortioxetine as a cost-318 
effective treatment option in this group of patients.  319 
NICE CG90 guidelines have highlighted the importance of having an antidepressant model that is 320 
comprehensive in its approach (9). Adverse events were not considered in the NICE model, this was 321 
also the case for many previously published models.(1, 46) The inclusion of safety and tolerability 322 
within MDD economic models is important, as patient’s safety when choosing treatment should be 323 
one of the primary considerations. While equivalent efficacy was considered between all treatments, 324 
the withdrawal due to AEs and tolerability had an important influence on the results. The lower 325 
withdrawal rates for vortioxetine compared to venlafaxine and duloxetine (5.93%, 28.20% and 28.20% 326 
respectively) support clinical opinion on the selection of treatments with more favourable tolerability 327 
profiles for patients who have not tolerated previous antidepressants.   328 
Limitations 329 
Although the favourable tolerability of vortioxetine has been reflected in the model to some extent, not 330 
all implications could be included. For example, the impact on decreased compliance to treatment, 331 
and premature cessation of treatment on clinical outcomes such as recurrence, have not been 332 
considered. In addition, the relative lack of discontinuation symptoms associated with vortioxetine 333 
compared to other antidepressants apart from agomelatine (Taylor et al. 2015) have not been 334 
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included in terms of either their impact on HRQoL or decrease in follow-up consultations where close 335 
monitoring of down-titration is necessary (47).  336 
Furthermore, a patient’s profile, previous treatment history including side-effects, and patient 337 
preference, determines the choice of suitable treatment options. Consequently, at later treatment lines 338 
the number of appropriate comparators will decrease. Explicitly modelling this proves challenging 339 
without increasing uncertainty in the results due to the vast number of additional assumptions 340 
required to support this.  341 
 342 
 343 
In MDD, a strict treatment pathway is unlikely to provide the optimal treatment strategy for this large 344 
and highly heterogeneous patient population. When choosing appropriate treatments, clinicians give 345 
consideration to individual treatment and patient profiles, including factors such as a patient’s 346 
previous treatment experience and preferences. Many of these aspects merit the consideration of 347 
vortioxetine with its different mode of action, and favourable safety and tolerability which are likely to 348 
translate into clinical and economic benefits for patients who have switched treatment.  349 
Conclusion 350 
Vortioxetine is an antidepressant with a unique mechanism of action. It has been shown to be at least 351 
as efficacious, and generally better tolerated, than other antidepressants in MDD. This has been 352 
observed consistently in the full MDD population through both direct head-to-head and indirect 353 
evidence. The model developed is a relatively accurate representation of the management of patients 354 
with recurrent MDD in the UK. The results of the base case analysis indicated that vortioxetine, with 355 
its tolerability benefits, is expected to be a cost-effective treatment option for patients experiencing an 356 
MDE after inadequate response to at least two previous antidepressants in the UK. The results of the 357 
study should be interpreted in light of the assumptions required for missing data on comparative 358 
effectiveness. These results are robust to the changes employed in scenario analyses conducted 359 
around treatment in both primary and secondary care, and length of maintenance treatment. 360 
 361 
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Figure 1. Model structure 
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Supplementary material 
Figure 2S. Vortioxetine vs. venlafaxine (equivalent efficacy)  
 
Figure 3S. Vortioxetine vs. duloxetine (equivalent efficacy)  
 
Figure 4S. Vortioxetine vs. agomelatine (equivalent efficacy) 
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Supplementary Material  
To allow for comparison across all the studies, the relevant results were presented based on odds 
ratios (OR) using vortioxetine as the reference. 
Table 6S. Comparison of data sources 
 Montgomery et al. 
(2014) (10)
 ¥
 
Switch 
Network 
(NICE 
submission; 
2015) (14, 15)
¥
 
Llorca et al. (2014) 
(23) 
Pae et al. 
(2015) (24) 
Wang et al. 
(2015) (26) 
Description of the data source 
Main objective 
of the study 
This randomised, 
double-blind, 12-
week study 
compared efficacy 
and tolerability of 
flexible-dose 
treatment with 
vortioxetine 
(10–20 mg/day) 
versus agomelatine 
(25–50 mg/day) in 
MDD patients with 
inadequate response 
to 
SSRI/SNRI 
monotherapy 
To assess the 
relative 
efficacy and 
tolerability of 
vortioxetine 
against 
different 
antidepressant 
monotherapies 
in patients with 
MDD with 
inadequate 
response to 
SSRI or SNRI 
therapy. 
Indirect Comparisons 
of 
efficacy and 
tolerability between 
active treatments and 
vortioxetine using 
meta-regression in 
MDD patients 
A meta-
regression in 
short-term 
vortioxetine 
trials to assess 
the efficacy, 
discontinuation 
rate and side 
effects in MDD 
patients 
This randomized, 
double-blind 8 
week study 
compared the 
efficacy and 
tolerability of 
fixed-dose 
treatment with 
vortioxetine 
(10  mg/day) and 
venlafaxine 
extended release 
(XR) 
(150  mg/day) in 
MDD patients 
Population  MDD patients with 
inadequate response 
to SSRI or SNRI 
MDD patients 
with 
inadequate 
response to 
SSRI or SNRI 
MDD patients 
 
MDD patients MDD patients 
Methods Randomised 
Controlled Trial 
Indirect 
treatment 
comparisons 
(Bucher 
method) 
Indirect treatment 
comparisons (meta-
regression) 
Meta-analysis Randomised 
Controlled Trial 
Primary 
outcomes in the 
data source 
Efficacy: Change 
from baseline to 
week 8 in MADRS 
total score 
Tolerability: 
Withdrawal due to 
AEs 
Efficacy: 
Remission 
Tolerability: 
Withdrawal 
due to adverse 
events 
Efficacy: Standardized 
mean difference in 
change from baseline 
to 2 months on 
primary endpoint 
[MADRS/HAM-D]) 
Tolerability: 
withdrawal rate due to 
adverse events. 
Efficacy: Mean 
change from 
baseline on 
MADRS/HAM-
D 
Tolerability: 
withdrawal due 
to AEs 
Efficacy: Change 
from baseline to 
week 8 in 
MADRS total 
score 
Tolerability: 
Withdrawal due to 
AEs 
Time point of 
assessment  
8 weeks 8 weeks 8 weeks 12 weeks 8 weeks 
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 Montgomery et al. 
(2014) (10)
 ¥
 
Switch 
Network 
(NICE 
submission; 
2015) (14, 15)
¥
 
Llorca et al. (2014) 
(23) 
Pae et al. 
(2015) (24) 
Wang et al. 
(2015) (26) 
Input data used in the CEA 
Efficacy parameters – Remission 
Remission 
definition  
(Study measure) 
MADRS total score 
(%) 
A score of ≤7 
on the HAM-D 
scale or ≤10 on 
the MADRS 
(Relative 
difference) 
SMD in change from 
baseline to 2 months 
on primary endpoint 
[MADRS/HAM-D] 
(SMD) 
A score of ≤7 
on the HAM-D 
scale or ≤10 on 
the MADRS 
(OR) 
MADRS total 
score (%) 
Remission rates      
     Vortioxetine  Reference 
(OR)* 
Reference 
(OR)* 
Reference 
(OR)* 
Reference 
(OR)* 
Reference 
(OR)* 
     Agomelatine  1.63 [95% CI: 1.12; 
2.37] 
1.63 [95% CI: 
1.12; 2.37] 
1.20 (p=0.470) 
0.84 [95% CI: 
0.58; 1.24] 
NA 
     Venlafaxine NE 1.26 [95% CI: 
0.52; 3.07] 
0.69 (p=0.444) 1.07 [95% CI: 
0.73; 1.57] 
     Duloxetine NE NE 0.89 (p=0.526) NE 
     Escitalopram NE NE 0.99 (p=0.981) NE NE 
     Citalopram NE 1.98 [95% 
CI:0.59; 6.60] 
NE NE NE 
     Sertraline NE 1.94 [95% CI: 
0.90; 4.20] 
NE NE NE 
Tolerability parameters – Withdrawal rates due to adverse events 
Withdrawal 
rates due AEs 
(Study measure) 
% Risk difference OR OR OR 
     Vortioxetine  Reference 
(OR)** 
Reference 
(OR)** 
Reference 
(OR)** 
Reference 
(OR)** 
Reference 
(OR)** 
     Agomelatine  0.60 [95% CI: 0.31; 
1.18] 
0.60 [95% CI: 
0.31; 1.18] 
1.77 (p=0.03) 
0.73 [95% CI: 
0.55; 0.96] 
NA 
     Venlafaxine NE 0.16 [95% CI: 
0.4; 0.76] 
0.47, (p=0.01) 0.43 [95% CI; 
0.22; 0.83] 
     Duloxetine NE NE 0.75 (p=0.26) NE 
     Escitalopram NE NE 0.67 (p=0.28) NE NE 
     Citalopram NE 0.15 [95% CI: 
0.02;0.86] 
NE NE NE 
     Sertraline NE 0.17 [95% CI: 
0.04;0.73] 
NE NE NE 
AEs: Adverse events; HAM-D: Hamilton Depression Rating Scale; MDD: Major Depressive Disorder; MADRS: Montgomery-
Asberg Depression Scale; NE: Not evaluated; OR: Odds Ratio; SMD: Standard mean difference; SNRI: serotonin–
norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor 
¥ Montgomery et al. (2014) was the starting point for the Switch Network  
*Odds ratio >1 favours vortioxetine 
**Odds ratio <1 favours vortioxetine 
 
 
 
 
Table 7S. Adjustment to third-line based on STAR*D 
Line  Remission probability No response (1-response) probability 
STAR*D REVIVE – vortioxetine STAR*D REVIVE – vortioxetine 
2nd 30.6% 40.5% 71.5% 38.5% 
 3rd 13.7% 18.13%* 83.2% 44.8%* 
*Proportional reduction in efficacy from second to third-line applied from STAR*D. 
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Equation 1S. Calculating the one-month relapse rate 
                                 
Equation 2S. Converting the relapse rate to a two-month probability 
                        
Table 8S. Health care resource utilisation by health state 
Healthcare resource 
utilization 
 No. of visits Patients with 
 ≥1 visit (%) 
Source 
GP consultations  Remission 0-8 weeks  2.50 100.0% PERFORM (38) 
No response 0-8 weeks 2.80 100.0% PERFORM (38) 
Response 0-8 weeks 2.50 100.0% Assumed equivalent to remission 
Remission 8-12 weeks 1.25 100.0% Calculation 
Response 8-12 weeks 1.25 100.0% Assumed equivalent to remission 
No response 8-12 weeks 1.40 100.0% Calculation; assumption 
Remission after 12 weeks  2.15 100.0% Byford et al. 2011(39) 
Response after 12 weeks  2.15 100.0% Assumed equivalent to remission 
Relapse after 12 weeks  2.89 100.0% Byford et al. 2011 (39) 
Psychiatrist consultations Remission 0-8 weeks  0.00 0.0% PERFORM (38) 
No response 0-8 weeks 1.00 1.3% PERFORM (38) 
Response 0-8 weeks 0.00 0.0% Assumed equivalent to remission 
Remission 8-12 weeks 0.00 0.0% Calculation; assumption 
Response 8-12 weeks 0.00 0.0% Assumed equivalent to remission 
No response 8-12 weeks 0.50 1.3% Calculation; assumption 
Remission after 12 weeks  0.23 2.9% Byford et al. 2011 (39) 
Response after 12 weeks  0.23 2.9% Assumed equivalent to remission 
Relapse after 12 weeks  0.23 5.0% Byford et al. 2011 (39) 
Psychotherapy or counselling  Remission 0-8 weeks  1.20 12.7% PERFORM (38) 
No response 0-8 weeks 2.10 18.8% PERFORM (38) 
Response 0-8 weeks 1.20 12.7% Assumed equivalent to remission 
Remission 8-12 weeks 0.60 12.7% Calculation; assumption 
Response 8-12 weeks 0.60 12.7% Assumed equivalent to remission 
No response 8-12 weeks 1.05 18.8% Calculation; assumption 
Remission after 12 weeks  0.00 0.2% Byford et al. 2011 (39) 
Response after 12 weeks  0.00 0.0% Assumed equivalent to remission 
Relapse after 12 weeks  0.00 0.2% Byford et al. 2011 (39) 
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    Mean 
number of 
days 
Patients 
with ≥1 
visit by 
ward (%) 
 
Psychiatric ward admissions Remission 0-8 weeks  0.00 0.0% PERFORM (38) 
No response 0-8 weeks 0.00 0.0% PERFORM (38) 
Response 0-8 weeks 0.00 0.0% Assumed equivalent to remission 
Remission 8-12 weeks 0.00 0.0% Calculation; assumption 
Response 8-12 weeks 0.00 0.0% Assumed equivalent to remission 
No response 8-12 weeks 0.00 0.0% Calculation; assumption 
Remission after 12 weeks  0.22 5.2% Byford et al. 2011 (39) 
Response after 12 weeks  0.22 5.2% Assumed equivalent to remission 
Relapse after 12 weeks  0.23 5.7% Byford et al. 2011 (39) 
General ward admissions Remission 0-8 weeks  0.00 0.0% PERFORM (38) 
No response 0-8 weeks 0.00 0.0% PERFORM (38) 
Response 0-8 weeks 0.00 0.0% Assumed equivalent to remission 
Remission 8-12 weeks 0.00 0.0% Calculation; assumption 
Response 8-12 weeks 0.00 0.0% Assumed equivalent to remission 
No response 8-12 weeks 0.00 0.0% Calculation; assumption 
Remission after 12weeks  0.00 0.0% Assumed equivalent to acute phase 
Response after 12 weeks  0.00 0.0% Assumed equivalent to remission 
Relapse after 12 weeks  1.00 0.5% Assumed equivalent to acute phase 
Accident & Emergency visits  Remission 0-8 weeks  0.00 0.0% PERFORM (38) 
No response 0-8 weeks 0.00 0.0% PERFORM (38) 
Response 0-8 weeks 0.00 0.0% Assumed equivalent to remission 
Remission 8-12 weeks 0.00 0.0% Calculation; assumption 
Response 8-12 weeks 0.00 0.0% Assumed equivalent to remission 
No response 8-12 weeks 0.00 0.0% Calculation; assumption 
Remission after 12 weeks  0.22 3.1% Byford et al. 2011 (39) 
Response after 12 weeks  0.22 3.1% Assumed equivalent to remission 
Relapse after 12 weeks  0.25 3.3% Byford et al. 2011 (39) 
 
Table 9S. Scenario results  
Treatments Total 
cost 
Total 
QALYs 
ICER (vortioxetine vs. 
comparator) 
Incremental ICERS 
(Including SSRIs; QALY) 
Incremental ICERS 
(Excluding SSRIs; QALY) 
Scenario 1: Patients managed in secondary care (Equivalent efficacy) 
Vortioxetine £3,033 1.427 Reference Reference Reference 
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Citalopram £3,073 1.414 Dominant Dominated n/a 
Escitalopram £3,079 1.414 Dominant Dominated n/a 
Sertraline £3,088 1.412 Dominant Dominated n/a 
Venlafaxine £3,135 1.410 Dominant Dominated Dominated 
Agomelatine £3,263 1.428 £332,296* £332,296* £332,296* 
Duloxetine £3,284 1.411 Dominant Dominated Dominated 
Scenario: Patients managed in secondary care (Montgomery) 
Vortioxetine £3,033 1.427 Reference n/a Reference 
Agomelatine £3,572 1.380 Dominated n/a Dominated 
Scenario 2: Maintenance treatment up to 22 months and primary care (Equivalent efficacy) 
Citalopram £1,659 1.408 £22,664 Reference n/a 
Escitalopram £1,670 1.407 £20,628 Dominated n/a 
Sertraline £1,682 1.405 £16,763 Dominated n/a 
Venlafaxine £1,778 1.403 £8,846 Dominated Ref 
Vortioxetine £1,923 1.419 Reference £22,664 £8,846 
Duloxetine £2,184 1.404 Dominant Dominated Dominated 
Agomelatine £2,316 1.420 £700,807* £700,807 £700,807 
Scenario: Maintenance treatment up to 22 months and primary care (Montgomery) 
Vortioxetine £1,923 1.419 Reference n/a Reference 
Agomelatine £2,237 1.373 Dominant n/a Dominated 
Scenario: Maintenance treatment up to 22 months and secondary care (Equivalent efficacy) 
Citalopram £3,908 1.408 £18,616 Reference n/a 
Escitalopram £3,918 1.407 £16,787 Dominated n/a 
Sertraline £3,931 1.405 £13,522 Dominated n/a 
Venlafaxine £4,021 1.403 £6,289 Dominated Reference 
Vortioxetine £4,124 1.419 Reference £18,616 £6,289 
Duloxetine £4,428 1.404 Dominant Dominated Dominated 
Agomelatine £4,584 1.420 £827,762* £827,762 £827,762 
Scenario: Maintenance treatment up to 22 months and secondary care (Montgomery) 
Vortioxetine £4,124 1.419 Reference n/a Reference 
Agomelatine £4,543 1.373 Dominant n/a Dominated 
 
 
 
 
 
 
Highlights 
 
 Limited guidance exists for management of third-line patients with depression 
 The model accounts for management of depression, including inadequate response 
 Vortioxetine is efficacious, and has a favourable safety profile vs comparators 
 Vortioxetine proved to be a cost-effective treatment vs other antidepressants 
 
 
 
